Introduction to the Partnership
Er-Kim, a leading international pharmaceutical company, has announced a significant partnership with Immunocore. Together, they are set to distribute KIMMTRAK, an innovative treatment for uveal melanoma, in Turkey and its neighboring regions including the MENA, Caucasus, and CIS.
Understanding Uveal Melanoma
Uveal melanoma is a rare cancer that affects the eye. While it stands as the most common primary intraocular malignancy in adults, its occurrence remains low, leading to a challenging diagnosis. Alarmingly, up to 50% of those diagnosed may progress to metastatic stages, historically leaving many patients with poor prognoses.
Significance of KIMMTRAK
KIMMTRAK, or tebentafusp, is approved in various countries for treating adult patients who are HLA-A*02:01-positive and suffer from unresectable or metastatic uveal melanoma. This therapy presents a much-needed option for patients facing such a daunting diagnosis when typical treatment options may fall short.
Er-Kim's Commitment to Oncology
Mert Zorlular, CFO of Er-Kim, expressed enthusiasm for the partnership, highlighting the company's four decades of experience in providing innovative cancer treatments. The collaboration aims to enhance access for eligible patients throughout Turkey and surrounding regions where the need for effective treatments is high.
About Er-Kim
Founded in 1981, Er-Kim has made significant strides in biopharmaceutical innovation, partnering with over 40 global leaders in the field. Through its strategic models focused on sustainability, Er-Kim extends vital healthcare solutions to over 600 million patients, positioning itself as a trusted partner in the oncology community.
Er-Kim's Global Reach
With a robust team of over 300 dedicated professionals and revenues surpassing EUR 305 million, Er-Kim’s influence on healthcare is notable. The company's mission is to set new standards in commercialization and patient access, continuously striving to expand its service offerings globally.
KIMMTRAK in Focus
KIMMTRAK has already made its mark as a pioneering monotherapy for certain qualified patients. Its innovative approach to targeting HLA-A*02:01-positive uveal melanoma patients uniquely distinguishes it in the treatment landscape.
Monitoring Regulatory Approvals
It is important to note that the availability and prescribing conditions of KIMMTRAK may differ across countries, reflecting ongoing regulatory processes and considerations in healthcare delivery.
Media Contact Details
For further inquiries, reach out to:
Rosalia Scampoli
Marketcom PR
Tel: (914) 815-1465
Email: rscampoli@marketcompr.com
Frequently Asked Questions
What is the purpose of the Er-Kim and Immunocore partnership?
The partnership aims to distribute KIMMTRAK for treating uveal melanoma in various regions, enhancing access to innovative therapies.
What is uveal melanoma?
Uveal melanoma is a rare eye cancer, and it is the most common form of primary intraocular malignancy in adults, but remains challenging to diagnose.
What is KIMMTRAK?
KIMMTRAK (tebentafusp) is a treatment approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.
How does KIMMTRAK work?
KIMMTRAK employs innovative immunotherapeutic techniques to target and potentially improve outcomes for patients with specific cancer types.
Who can access KIMMTRAK?
The treatment is intended for HLA-A*02:01-positive adults with severe cases of uveal melanoma, subject to approval in specific countries.
